ClinicalTrials.gg
Active, not recruitingNCT05855135INTEGRA-DUpdated Nov 6, 2026

Assessment of Combined CCM and ICD Device in HFrEF

An interventional study of OPTIMIZER® Integra CCM-D System (Treatment Arm) in Heart Failure, Heart Failure With Reduced Ejection Fraction and Implantable Defibrillator User, sponsored by Impulse Dynamics. Active, not recruiting at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Impulse Dynamics · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure by Impulse Dynamics — 4 open to participants now, 6 under way, none of them phase 3. Heart Failure · Impulse Dynamics.

Started
2023
the only one that year
No phase
7 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Heart Failure by Impulse Dynamics, this one is the only one that started in 2023, is one of 7 with no phase, and was the 8th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 11 studies in Heart Failure by Impulse Dynamics are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by Impulse Dynamics, or all of them as a file.
02

Study summary

The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).

Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.

03

Conditions studied

  • Heart Failure
  • Heart Failure With Reduced Ejection Fraction
  • Implantable Defibrillator User
  • CCM Therapy
  • Non-ischemic Cardiomyopathy
  • Ischemic Cardiomyopathy
  • Sudden Cardiac Arrest
  • Arrhythmias, Cardiac
  • Ventricular Tachycardia
  • Ventricular Fibrillation

Keywords

  • Heart Failure
  • HFrEF
  • Stage C Heart Failure
  • Stage D Heart Failure
  • Defibrillation Efficacy Testing
  • Induced Ventricular Fibrillation
  • Ventricular fibrillation
  • Ventricular tachycardia
  • Implantable cardioverter defibrillator
  • Sudden cardiac arrest
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals must meet all the following:

  1. Patient is aged 18 years or older;
  2. Patient meets the Stage C or D criteria of the Universal Definition of Heart Failure ;
  3. Patient has HFrEF ( ≤40%);
  4. Patient is on GDMT for heart failure;
  5. Patient has a Class I or Class II indication for an ICD
  6. Patient has a reasonable expectation of meaningful survival of > 1 year;
  7. Patient has either non-ischemic cardiomyopathy or ischemic cardiomyopathy and is at least 40 days post-MI, if an MI occurred;
  8. Patient is willing to give , available for scheduled study follow-up visits, and able to complete all testing described in the study protocol at the site location.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Patients should not have severe AI or AS, and should not have MS; additionally, patients undergoing DE testing should not have severe MR;
  2. Patients who have undergone mitral valve repair or clip within 90 days prior to study consent;
  3. Cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
  4. Prior heart transplant or ventricular assist device;
  5. Implanted mechanical tricuspid valve;
  6. PR interval greater than 375ms or advanced AV block;
  7. In situ S-ICD, pacemaker, or CRT device;
  8. Indicated for CRT;
  9. End stage renal disease, currently on dialysis, or with other major medical disorder (e.g. liver failure, terminal cancer);
  10. Indicated for permanent bradyarrhythmia pacing;
  11. Unstable angina pectoris within 30 days prior to study consent;
  12. Pregnant or planning to become pregnant during the study;
  13. Participating in another cardiac device or drug study at the same time (or within 30 days prior to study consent); Note: Registries and other observational studies are acceptable.
  14. Other criteria that preclude Optimizer INTEGRA CCM-D implantation and/or CCM therapy, as determined by Investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    CCM-D Implant

    The subject is implanted with the CCM-D device.

    Device: OPTIMIZER® Integra CCM-D System (Treatment Arm)

Interventions

  • DeviceOPTIMIZER® Integra CCM-D System (Treatment Arm)

    The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a "Cardiac Contractility Modulation - Defibrillator". All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years.

06

What researchers measure

Primary outcomes

  1. Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)

    Evaluate the device effectiveness in converting induced VF at the time of implantation.

    Time frame: Implant

  2. Device-related Complications (Primary Safety Objective)

    Evaluate device-related complications through 6-months (excluding lead-related complications).

    Time frame: Implant to 6 months

Secondary outcomes

  1. Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)

    Evaluate the incidence of inappropriate ICD shocks through the time when the last subject enrolled completes the 6-month visit.

    Time frame: Implant to 6 months

Other outcomes

  1. Inappropriate Shock Rate out to 2-years

    Evaluate the device effectiveness in converting spontaneous VT/VF through the time when the last subject enrolled completes the 6-month visit. Each subject will be followed for 2-years after implant to capture additional spontaneous episodes that may occur.

    Time frame: Implant to 2 years

  2. Charging non-compliance

    Evaluate subject charging non-compliance defined as \>14 days between interval charging sessions, overall and frequency of non-compliance in the same subject.

    Time frame: Implant to 2 years

  3. Longitudinal levels of activity

    Track longitudinal levels of activity weekly via OPTIhome (when available) and identification of trends.

    Time frame: Implant to 2 years

  4. Battery degradation and longevity

    Assess battery degradation and longevity either remotely or during an in-person follow-up at 2 years (+/- 60 days) by recording QHR battery voltage as measured by the Integra CCM-D IPG. The measurement under nominal conditions is expected to be 2.85V or higher, consistent with a 20-year device longevity.

    Time frame: Implant to 2 years

  5. Compare worsening heart failure events pre- and post-implant

    Track unscheduled cardiovascular-related healthcare encounters from 12 months prior to implant, if available, to 12 months post-implant

    Time frame: 12 months prior to implant and 12 months post-implant

  6. All-cause mortality

    Assess all-cause mortality using Seattle Heart Failure Model (SHFM) and comorbidity burden as a predictive comparator at 1 year and 2 years post-implant

    Time frame: 1 and 2 years post-implant

  7. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Compare change in subject's perception of their heart failure symptoms, as measured by KCCQ, from baseline to 6 months.

    Time frame: Baseline to 6-months

  8. EQ-5D-5L

    Compare change in subject's perception of their health status, as measured by the EQ-5D-5L, from baseline to 6 months.

    Time frame: Baseline to 6-months

  9. Six Minute Walk Distance (6MWD)

    Compare change in functional capacity, as measured by 6MWD, from baseline to 6 months.

    Time frame: Baseline to 6 months

07

Study locations

59 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2025, 31 months.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's 31 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Dec 2025, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 11, 2023
StartActual
May 17, 2023
Primary completionActual
Dec 31, 2025was May 2026
CompletionEst.
Jul 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→Dec 31, 2025 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion May 2026→Dec 31, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05855135
Lead sponsor
Impulse Dynamics
Responsible party
Sponsor
First posted
May 11, 2023
Start date
May 17, 2023
Primary completion
Dec 31, 2025
Completion
Jul 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Niraj Varma, MD, PhD
principal investigator · The Cleveland Clinic
Nir Uriel, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion